In a weighted, variable-adjusted cohort using pairwise comparisons, GLP-1 RAs were associated with a modest but significant reduction in MACE and heart failure hospitalizations compared to DPP-4 inhibitors, with an adjusted risk difference of 3.2 events per 1000 person-years. This evidence concerns the gene GLP1R and heart failure.